- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma Inc stock price live, this page displays NASDAQ LYEL stock exchange data. View the LYEL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lyell Immunopharma Inc real time stock price chart below.
What Is the Lyell Immunopharma Inc Stock Price Today?
The Lyell Immunopharma Inc stock price today is 15.530.
What Is the Stock Symbol for Lyell Immunopharma Inc?
The stock symbol for Lyell Immunopharma Inc is "LYEL."
What Stock Exchange Does Lyell Immunopharma Inc Trade On?
Lyell Immunopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Lyell Immunopharma Inc a Good Stock to Buy?
Determining whether Lyell Immunopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LYEL quote. (ISIN: US55083R2031)
What Is the Lyell Immunopharma Inc Stock Price Today?
The Lyell Immunopharma Inc stock price today is 15.530.
What Is the Stock Symbol for Lyell Immunopharma Inc?
The stock symbol for Lyell Immunopharma Inc is "LYEL."
What Stock Exchange Does Lyell Immunopharma Inc Trade On?
Lyell Immunopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Lyell Immunopharma Inc a Good Stock to Buy?
Determining whether Lyell Immunopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LYEL quote. (ISIN: US55083R2031)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.200
16.160
52 wk Range
10.560
45.000
LYEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.20016.160
52 wk Range
10.56045.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LYEL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
37.875
Upside
+143.88%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
0 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 37.875
(+143.88% Upside)
Earnings
Latest Release
Aug 12, 2026
EPS / Forecast
-1.92 / -2.14
Revenue / Forecast
4K / 5.5K
Compare LYEL to Peers and Sector
Metrics to compare | LYEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLYELPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −3.3x | −0.3x | |
PEG Ratio | −0.03 | −0.05 | 0.00 | |
Price/Book | 1.6x | 4.5x | 2.6x | |
Price / LTM Sales | 14,095.0x | 6.6x | 3.1x | |
Upside (Analyst Target) | 165.8% | 262.0% | 47.6% | |
Fair Value Upside | Unlock | 13.3% | 5.6% | Unlock |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Lyell Immunopharma (LYEL) Stock Price Today?
The Lyell Immunopharma stock price today is 15.530 USD.
What Stock Exchange Does Lyell Immunopharma Trade On?
Lyell Immunopharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lyell Immunopharma?
The stock symbol for Lyell Immunopharma is "LYEL."
What Is the Lyell Immunopharma Market Cap?
As of today, Lyell Immunopharma market cap is 376.150M USD.
What Is Lyell Immunopharma's Earnings Per Share (TTM)?
The Lyell Immunopharma EPS (TTM) is -11.822.
When Is the Next Lyell Immunopharma Earnings Date?
Lyell Immunopharma will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is LYEL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Lyell Immunopharma Stock Split?
Lyell Immunopharma has split 1 times.
How Many Employees Does Lyell Immunopharma Have?
Lyell Immunopharma has 161 employees.
What is the current trading status of Lyell Immunopharma (LYEL)?
As of Aug 22, 2026, Lyell Immunopharma (LYEL) is trading at a price of 15.530 USD, with a previous close of 15.350 USD. The stock has fluctuated within a day range of 15.200 USD to 16.160 USD, while its 52-week range spans from 10.560 USD to 45.000 USD.
What Is Lyell Immunopharma (LYEL) Price Target According to Analysts?
The average 12-month price target for Lyell Immunopharma is 37.875 USD, with a high estimate of 49 USD and a low estimate of 12 USD. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +143.88% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.